<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01844752</url>
  </required_header>
  <id_info>
    <org_study_id>NI-AC201</org_study_id>
    <nct_id>NCT01844752</nct_id>
  </id_info>
  <brief_title>A Phase 2, 3 Arm Study of NVN1000 Gel and Vehicle Gel in Subjects With Acne</brief_title>
  <official_title>A Multi-Center, Randomized, Evaluator-Blinded, Vehicle-Controlled, Parallel Group, 3-arm Study Comparing the Efficacy, Tolerability and Safety of 2 Concentrations of NVN1000 Gel and Vehicle Gel Twice Daily in the Treatment of Acne Vulgaris.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novan, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novan, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 12 week clinical trial in subjects with acne vulgaris. Subjects will be randomized
      to NVN1000 1% Gel, NVN1000 4% Gel or Vehicle Gel twice daily. Safety, tolerability and
      efficacy will be assessed over the course of the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, evaluator and subject blinded, randomized, vehicle-controlled,
      parallel group, dose-ranging study to be conducted in approximately 150 subjects with acne
      vulgaris. Subjects who satisfy the entry criteria at the Baseline visit will be randomized to
      NVN1000 1% Gel, NVN1000 4% Gel or Vehicle Gel in a 1:1:1 ratio. Efficacy assessments will
      include inflammatory and non-inflammatory lesion counts and investigator global assessments
      (IGA). Tolerability and safety assessments include cutaneous tolerability evaluation, adverse
      event collection, physical exams, and laboratory studies. Subjects will return for
      post-baseline evaluation at Weeks 2, 4, 8, and 12.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The absolute change from baseline in non-inflammatory lesion counts at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>The absolute change from baseline in non-inflammatory lesion counts at Week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The absolute change from baseline in inflammatory lesion counts at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>The absolute change from baseline in inflammatory lesion counts at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success on the Investigator Global Assessment (IGA) at Week 12</measure>
    <time_frame>12 week</time_frame>
    <description>Analysis of the dichotomized IGA scores (success vs failure) at Week 12. &quot;Success&quot; is defined as a score of &quot;clear&quot; or &quot;almost clear&quot; and a 2 point improvement in the IGA score from Baseline.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>NVN1000 1% Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NVN1000 1% Gel twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVN1000 4% Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NVN1000 4% Gel twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle Gel twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVN1000 1% Gel</intervention_name>
    <description>Twice daily NVN1000 1% Gel for 12 weeks</description>
    <arm_group_label>NVN1000 1% Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVN1000 4% Gel</intervention_name>
    <description>Twice daily NVN1000 4% Gel for 12 weeks</description>
    <arm_group_label>NVN1000 4% Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Gel</intervention_name>
    <description>Twice daily Vehicle Gel for 12 weeks</description>
    <arm_group_label>Vehicle Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with acne vulgaris and at least 20 but no more than 40 inflammatory lesions,
             25-70 non-inflammatory lesions, no more than 2 nodules on the face

          -  Baseline IGA score of mild, moderate or severe

          -  Women of child-bearing potential must agree to use an effective method of birth
             control during the study and for 30 days after their final study visit

        Exclusion Criteria:

          -  Any dermatologic condition or other medical problem that could interfere with clinical
             evaluation or requires the use of topical or systemic therapy that make evaluations
             and lesion count inconclusive

          -  Female subjects who are pregnant, nursing, or considering becoming pregnant

          -  Methemoglobin &gt; 2% at baseline

          -  Clinically significant anemia at baseline

          -  Use of topical or systemic medications to treat acne

          -  Use of medications that make acne worse, associated with methemoglobinemia, or nitric
             oxide donors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joyce Rico, MD</last_name>
    <role>Study Director</role>
    <affiliation>Novan, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Dermatologico &amp; Cirugia de Piel</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Y Clinica Bendana</name>
      <address>
        <city>San Pedro Sula</city>
        <country>Honduras</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosptal Punta Pacifica</name>
      <address>
        <city>Panama City</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Dominican Republic</country>
    <country>Honduras</country>
    <country>Panama</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2013</study_first_submitted>
  <study_first_submitted_qc>April 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2013</study_first_posted>
  <last_update_submitted>January 10, 2014</last_update_submitted>
  <last_update_submitted_qc>January 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acne</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

